Skip to Content

Immutep Ltd PRRUF

Morningstar Rating
$0.26 +0.02 (10.04%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

PRRUF is trading at a 516% premium.
Price
$0.26
Fair Value
$8.46
Uncertainty
Extreme
1-Star Price
$4.48
5-Star Price
$2.36
Economic Moat
Yzy
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PRRUF is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.24
Day Range
$0.260.28
52-Week Range
$0.140.31
Bid/Ask
$0.19 / $0.40
Market Cap
$313.97 Mil
Volume/Avg
9,090 / 5,899

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
41

Comparables

Valuation

Metric
PRRUF
02315
IMU
Price/Earnings (Normalized)
Price/Book Value
4.013.452.17
Price/Sales
3.77
Price/Cash Flow
Price/Earnings
PRRUF
02315
IMU

Financial Strength

Metric
PRRUF
02315
IMU
Quick Ratio
16.760.965.46
Current Ratio
17.241.255.73
Interest Coverage
−2.91
Quick Ratio
PRRUF
02315
IMU

Profitability

Metric
PRRUF
02315
IMU
Return on Assets (Normalized)
−13.53%
Return on Equity (Normalized)
−37.28%
Return on Invested Capital (Normalized)
−20.22%
Return on Assets
PRRUF
02315
IMU
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
LvdtmffhMvch$631.5 Bil
Vertex Pharmaceuticals Inc
VRTX
WrcrhttqdCndycp$121.0 Bil
Regeneron Pharmaceuticals Inc
REGN
BfsbshgcVmwwbn$116.0 Bil
Moderna Inc
MRNA
WsfjhljzRgqy$51.1 Bil
argenx SE ADR
ARGX
KywccfhnGjyg$23.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
BdyzwyqrNjqptqv$21.0 Bil
BioNTech SE ADR
BNTX
MwrjmvztTngq$20.4 Bil
Biomarin Pharmaceutical Inc
BMRN
DkbnmzftPrrvqy$15.9 Bil
United Therapeutics Corp
UTHR
CynwwvpqHkx$14.0 Bil
Incyte Corp
INCY
ZjlnkqlsZcpznzm$12.5 Bil

Sponsor Center